Claseprubart efficacy and safety
1 evidence topic · 5 sources
Summary
No randomized efficacy results for claseprubart in CIDP have been reported. CAPTIVATE is a phase 3 trial with an open-label Part A, in which participants receive claseprubart 300 mg subcutaneously every 2 weeks after an intravenous loading dose, followed by a randomized, placebo-controlled withdrawal Part B with time to relapse on the adjusted INCAT score as the primary endpoint. In the interim responder analysis of Part A, 30 of the first 40 participants (75%) were confirmed responders, defined as a decrease of at least 1 point in the adjusted INCAT score, against a target response rate of 50% or greater. Of the 10 non-responders, 5 had stable CIDP and 5 had a relapse. In confirmed responders, the mean (SD) change from Part A baseline was –1.6 (0.89) on INCAT, 15.9 (12.78) in grip strength, 5.1 (3.93) on the MRC-SS, and 8.9 (12.08) on I-RODS.
In the same interim analysis set (N=40), 24 participants (60%) had an adverse event and 1 (3%) had a serious adverse event, a grade 3 ureterolithiasis assessed as not treatment-related. No treatment-related infections, serious infections, or adverse events leading to discontinuation were reported. In the phase 1 study in healthy volunteers, no serious adverse events were reported, five participants had mild or moderate treatment-related adverse events, and two participants in the 50 mg/kg intravenous cohort became antinuclear antibody positive at Day 57 without evidence of SLE.
These results are from an interim analysis of the open-label Part A; the company describes the summaries as preliminary and states that the study remains ongoing and the data are not final. Top-line results from all participants completing Part A are expected by the end of 2027 and from Part B by the end of 2028.